Revue medicale suisseSep 10, 2026

Blood pressure effects of strong GLP-1 and GIP hormone-like drugs

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Sep 11, 2026

Abstract

GLP-1 and GIP analogues reduce systolic blood pressure by up to 7.2 mmHg while promoting weight loss.

These agents are effective in reducing body weight.
The decrease in blood pressure may contribute to cardiovascular protection.
Potential mechanisms include interactions with weight, blood vessels, nerves, kidneys, and inflammation.
Weight loss with these treatments may enhance adherence to medication compared to other blood pressure therapies.
GLP-1 and GIP analogues could be considered for future use in treating high blood pressure in overweight or obese individuals.

Simplified

Potent analogues of GLP-1 and GIP are used in the indication of weight reduction. In addition to their significant effects on body weight., these agents reduce systolic blood pressure up to 7,2mmHg. The reduction in blood pressure partly explains the substantial cardiovascular protective effect observed with these molecules. The underlying mechanisms are multifactorial, involving weight-related, vascular, neurogenic, renal, and anti-inflammatory pathways. The desired effect on weight leads to improved treatment adherence compared with other anti-hypertensive therapeutic modalities. Consequently GLP-1 and GIP analogues could potentially be used for antihypertensive indications in the future for overweight or obese patients.

Blood pressure effects of strong GLP-1 and GIP hormone-like drugs

Abstract

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief